期刊文献+

二甲双胍与格列美脲治疗T2DM的有效性及安全性

下载PDF
导出
摘要 目的分析探究二甲双胍与格列美脲在2型糖尿病患者治疗中的效果及治疗的安全性。方法选择2017年10月1日到2018年4月30日期间在我单位就诊且确诊为2型糖尿病的100例患者作为本次试验的研究对象,按照病历的单双号不同进行分组,将病历号为单号的患者作为对照组给予格列美脲单药治疗,病历号双号的患者作为观察组给予格列美脲联合二甲双胍双药治疗,观察两组糖尿病患者治疗前后糖化血红蛋白、空腹血糖、餐后2h血糖的变化情况及低血糖反应的发生率。结果无论单药还是两种药物的联合治疗,糖尿病患者的空腹血糖、餐后血糖、糖化血红蛋白的值均下降,与对照组相比较,观察组下降的幅度更大,有差异,具有统计学意义(P <0. 05)。且经双药联合治疗的观察组低血糖发生率低于对照组,有差异,具有统计学意义(P <0. 05)。结论二甲双胍与格列美脲在2型糖尿病患者治疗中效果较佳,低血糖不良反应较小,值得在临床上进行推广。
作者 彭丽云
出处 《海峡药学》 2018年第10期199-200,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献5

二级参考文献83

  • 1Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 updated March 2011[OL].Cochrane website, www.cochrane-handbook.org. 2012-11-27/2012- 12-10.
  • 2Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase Ⅲ trial with a 34-week active-controlled extension [J]. Diabetes Obes Metab, 2012,.
  • 3Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial [J]. Diabetes Obes Metab, 2011, 13(3): 258-267.
  • 4Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin(BI 1356), a potent and selective DPP-4 inhibitor, is safe and etticacious in combination with metformin in patients with inadequately controlled Type 2 diabetes [J]. Diabet Meal, 2010, 27(12): 1409-1419.
  • 5Gomis R, Espadero R M, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes Obes Metab, 2011, 13(7): 653-661.
  • 6Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes Obes Metab, 2012, 14(6): 565-574.
  • 7Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glyeaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: arandomized, placebo and active comparator-controlled, double-blind study [J]. Diabetes Obes Metab, 2012, 14(4): 348-357.
  • 8Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial [J]. Clin Ther, 2012, 34(9): 1909-1919 el915.
  • 9Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study [J]. Diabet Med, 2011, 28(11): 1352-1361.
  • 10Ross S A, Rafeiro E, Meinicke T, et al. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial [J]. Curr Med Res Opin, 2012, 28(9): 1465-1474.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部